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Disease-specific induced pluripotent stem cells (iPSCs) are invaluable tools for studying genetic disorders in
a dish. A recent paper byWang et al. (2014) powerfully combines analysis of human iPSCs with genome edit-
ing and tissue engineering, in conjunction with biochemical and physiological assays, to provide insights into
Barth-syndrome-associated cardiomyopathy.Human induced pluripotent stem cell
(hiPSC) lines derived from patients
harboring disease-specific mutations
afford excellent opportunities for discov-
ering as-yet unknown molecular mecha-
nisms that underlie clinical manifestations
of genetic diseases. While differentiating
disease-relevant andpatient-specific lines
toward relevant cell types can relieve a
major limiting step in disease modeling,
i.e., can enable the creation of sufficient
quantities of appropriate cellular material
for performing mechanistic studies, draw-
ing useful insightswith these tools requires
development of appropriate cell-based
assays that assess relevant aspects of
the disease under study. A recent study
in Nature Medicine by Wang et al. (2014)
presents a tour-de-force coupling of
genome editing, tissue engineering, and
physiological characterization of patient-
specific hiPSC lines to provide novel
mechanistic insights into the pathophysi-
ology of, and potential treatment strate-
gies for, a genetic-mutation-associated
mitochondrial cardiomyopathy (Figure 1).
The study by Wang et al. (2014) ad-
dresses Barth syndrome (BTHS), a reces-
sive X-linked genetic disorder primarily
affecting males at an estimated incidence
of 1.5 cases per 1 million births (Rigaud
et al., 2013). BTHS is characterized
by cardiomyopathy, neutropenia, skeletal
myopathy, and growth delay. Symptoms
are usually observed early in infancy, but
age at presentation and severity vary
significantly among patients. BTHS is
caused by mutations in the TAZ gene,
located in Xq28 (Rigaud et al., 2013).
The gene encodes tafazzin, a phos-pholipid acyltransferase involved in re-
modeling of cardiolipin, a key lipid of
the mitochondrial inner membrane that
is necessary for the proper function
of the respiratory chain in the cells’
‘‘powerhouse.’’
Wang and coworkers established pa-
tient-specific BTHS hiPSC lines contain-
ing frameshift or missense mutations in
the TAZ gene and used established proto-
cols to differentiate them into cardio-
myocytes (BTHS hiPSC-CMs). Compared
to cardiomyocytes differentiated from
control hiPSC lines, the mitochondria
in BTHS hiPSC-CMs were smaller and
more fragmented and displayed elevated
basal oxygen consumption rates and
impaired electron transport chain activity.
In this study, these metabolic abnormal-
ities were notably not observed in primary
BTHS patient fibroblasts and respective
hiPSCs at the pluripotent stage, seem-
ingly underscoring the muscle-specific
phenotype of the disease.
In contrast, Dudek et al. recently
demonstrated preexisting aberrant respi-
ratory chain function in undifferentiated
iPSCs obtained from three BTHS patients
carrying discrete TAZ mutations (Dudek
et al., 2013). These cells showed mark-
edly decreased basal oxygen consump-
tion rates, together with a reduced mito-
chondrial membrane potential, increased
amounts of immature cardiolipin, and
elevated levels of mitochondrial reactive
oxygen species (ROS), presumably re-
sulting from the misassembly of mito-
chondrial respiratory chain supercom-
plexes. These findings highlight the need
to carefully investigate the effects of dis-Cell Stemease-specific mutations not only in the
cell type presumed to show the disease
phenotype but also in undifferentiated
cells and other differentiated derivatives
thereof in order to unequivocally delineate
tissue-specific effects, including potential
phenotypic heterogeneity, resulting from
different mutations.
Wang et al. then performed a series
of rigorous experiments to prove the
causative role of TAZ mutations in
abnormal heart function, irrespective of
the genomic background of the cells, us-
ing three independent approaches: (1)
shRNA-mediated knockdown of TAZ in
primary rat cardiomyocytes to confirm
the metabolic phenotype in primary cells
of another species, (2) phenotypic rescue
in BTHS hiPSC-CMs by transfection with
synthetic modified RNA (Warren et al.,
2010) encoding wild-type TAZ, and (3)
Cas9-mediated genome editing (Mali
et al., 2013) to introduce TAZ mutations
into isogenic control hiPSC lines. All
three approaches confirmed that TAZ
mutations alone are sufficient to cause
disease-specific abnormalities in cardio-
myocytes. Plating individual hiPSC-CMs
onto micropatterned fibronectin rectan-
gles to force them to adopt regular shapes
with fixed length/width ratios allowed pre-
cise comparisons of sarcomeric architec-
ture between cells. Notably, sarcomere
organization was found to be highly irreg-
ular in mutant cells, but it reverted to
normal upon the addition of wild-type
TAZ mRNA.
To connect their hiPSC-based in vitro
model to the failing heart phenotype
in Barth patients, Wang et al. applied aCell 15, July 3, 2014 ª2014 Elsevier Inc. 9
Figure 1. Modeling Barth Syndrome with Disease-Specific Induced Pluripotent Stem Cells
iPSCs are generated from patients suffering from Barth syndrome. Additionally, disease-specific mutations are introduced into wild-type iPSC lines enabling
direct comparison with isogenic controls. iPSC-derived cardiomyocytes are applied in a ‘‘heart-on-chip’’ assay to model the pathophysiology in vitro to inves-
tigate the underlying mechanism of Barth syndrome and to evaluate potential therapies.
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generated by seeding purified BTHS
hiPSC-CMs onto elastomeric substrates
with micropatterned lines of fibronectin,
allowing self-organization of the cells
into a laminar myocardium. The resultant
contractile muscular thin film (MTF)
constructs are then partially liberated
from supportive glass coverslips, allowing
them to contract and curl (Grosberg et al.,
2011). In contrast to alternative tissue
engineering approaches (Kensah et al.,
2013), MTF constructs do not allow direct
force measurement. Instead, video re-
cordings of MTFs bending after electrical
stimulation of cardiomyocyte contrac-
tions are used to calculate indirect param-
eters such as peak diastolic and systolic
stress. Using this system, BTHS hiPSC-
CMs from both patient-derived lines
were found to have reduced contractile
function, which could be corrected
by introducing TAZ mRNA. Interestingly,
cell lines with distinct TAZ mutations
were noted to have differences in the
levels of peak diastolic and systolic
stresses generated; however, the extent
of sarcomere disorganization did not
necessarily correlate with the decrease
in twitch stress, a measure of contrac-
tile force. Electrophysiological ana-
lyses were not performed, which would
have allowed the authors to deter-
mine whether observed TAZ-mutation-10 Cell Stem Cell 15, July 3, 2014 ª2014 Elsedependent phenotypes result in impaired
electromechanical coupling. Notably,
impaired coupling could reflect additional
clinical manifestations in BTHS, including
ventricular arrhythmias and sudden car-
diac death.
Wang et al. then leveraged their iPSC-
CM-based disease model to assess po-
tential therapeutic strategies for BTHS.
They found that both linoleic acid (a cardi-
olipin precursor and ROS scavenger) and
a structurally unrelated ROS scavenger,
mitoTEMPO, could rescue defects on
sarcomere organization and function.
Together, these observations provide an
intriguing link between impaired sarco-
mere formation (and weak force genera-
tion) in cardiomyocytes and elevated
levels of ROS, which appear to have re-
sulted from pathophysiological changes
in mitochondria causatively induced by
tafazzin mutations. This work has implica-
tions for related diseases such as familial
hypertrophic cardiomyopathies, which
are often induced by mutations in sarco-
meric genes such as b-MHC.
Wang et al. (2014) are among the first
to investigate the influence of genetically
based mitochondrial abnormalities on
cell function using patient-specific iPSCs.
Although mitochondrial dysfunction in
BTHS results from mutation in a nuclear-
encoded gene, this study may point to a
broader impact of mitochondrial dysfunc-vier Inc.tion on cell differentiation and maturation
and, ultimately, the function of termi-
nally differentiated and aging cells. Impor-
tantly, large mitochondrial deletions,
a common cause of mitochondrial dis-
eases, have been demonstrated in plurip-
otent stem cells (Van Haute et al., 2013)
and in aging processes (Bratic and Lars-
son, 2013). As targeted engineering
of the mitochondrial genome in iPSCs
becomes feasible (Bacman et al., 2013),
modeling mitochondrial diseases in
a dish or investigating the effect of age-re-
lated or reprogramming-associated accu-
mulation of heteroplasmic mutations on
iPSCs and the functionality of their deriva-
tives is an exciting task for the future.
Importantly, such studies will also help
to answer a highly clinically relevant ques-
tion: are iPSCs generated from aged indi-
viduals of a similar biological quality to
iPSCs made from young cell sources
such as cord blood, or should we initiate
the banking of primary cells at a neonatal
stage for the later generation of clinically
applicable iPSC products?REFERENCES
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